Siemens Healthineers secures US$83M public-private funding to scale photon flash radiotherapy

GERMANY—Siemens Healthineers’ Varian business has secured US$60 million in funding from the U.S. Advanced Research Projects Agency for Health (ARPA-H) over five years to accelerate the development of photon Flash radiotherapy, an ultra-high-dose-rate cancer treatment.

In addition to this federal award, Siemens Healthineers will contribute U$23 million in cost-share investments over the same period, bringing the total commitment to $83 million.

The funding ranks among the larger U.S. government investments in medical technology innovation and supports efforts to adapt Flash therapy for use on widely available linear accelerators already used in hospitals.

Advancing photon flash radiotherapy technology

Photon Flash radiotherapy delivers radiation more than 100 times faster than conventional radiotherapy techniques, to reduce damage to surrounding healthy tissue while effectively targeting tumors.

This approach is designed to expand treatment options for cancers located near sensitive organs where side effects can limit traditional radiotherapy.

Unlike earlier Flash research that has focused mainly on proton and electron beam systems, Siemens Healthineers is prioritizing photon-based systems.

The company aims to overcome scalability and access challenges associated with proton and electron platforms, which are costly and not widely available.

Recent Varian research activity has already demonstrated progress in ultra-high-dose-rate treatment systems, including clinical trial developments such as Flash-enabled proton therapy workflows and integrated planning tools to support experimental radiotherapy delivery systems.

Integration into existing clinical infrastructure

Siemens Healthineers is working to ensure that Photon Flash technology can operate within existing hospital workflows.

The company plans to build on its installed base of C-arm linear accelerators to support faster clinical translation and broader global access.

The strategy also aligns with broader developments within the company’s Precision Therapy segment, which has continued to show stable growth driven by demand for advanced cancer treatment technologies and digital-enabled radiotherapy systems.

Industry and research community response

Arthur Kaindl, head of Varian at Siemens Healthineers, said the ARPA-H funding strengthens ongoing research into Flash therapy and supports efforts to expand future treatment options for cancer patients.

He noted that leveraging existing linear accelerator infrastructure could accelerate adoption if clinical validation proves successful.

Sameer R. Keole, chair of the American Society for Radiation Oncology (ASTRO) Board of Directors, described the ARPA-H award as a milestone for radiation oncology, emphasizing its role in advancing safer and more efficient cancer treatments.

Matthias Guckenberger, president of the European Society for Radiotherapy and Oncology (ESTRO), highlighted the long-standing underfunding of radiotherapy research and noted that increased public investment could help close innovation gaps in cancer care.

Broader Corporate and Research Developments

In recent updates, Siemens Healthineers has continued to expand its oncology and precision therapy portfolio.

The company recently supported new regulatory progress for Varian radiotherapy systems, including expanded clinical applications of low-dose radiation therapies beyond oncology, reflecting broader diversification in therapeutic applications.

Additionally, Siemens Healthineers has maintained investment momentum in imaging, diagnostics, and AI-enabled clinical solutions as part of its “Elevating Health Globally” strategy, which focuses on integrating advanced technologies across healthcare systems.

Varian, which operates as Siemens Healthineers’ cancer care division, continues to play a central role in the company’s oncology innovation strategy, particularly in radiation oncology platforms designed to improve treatment precision and efficiency.

Outlook for Photon Flash Development

Siemens Healthineers intends to use the ARPA-H-supported program to further develop scalable photon Flash systems compatible with clinical environments worldwide.

The company is focusing on aligning experimental high-dose-rate radiotherapy with established hospital infrastructure to reduce barriers to adoption and expand access to advanced cancer treatment technologies across diverse healthcare settings.